Aristo Bio-Tech and Lifescience H1 FY27 profit rises 17.6%
Key highlights
- Aristo Bio-Tech and Lifescience reported H1 FY27 net profit of ₹4.90 crore, up 17.6% year on year.
- Revenue from operations fell 22.7% year on year to ₹198.24 crore in H1 FY27.
- Profit before tax increased 19.0% year on year to ₹6.60 crore.
- Trade receivables rose to ₹113.84 crore on September 30, 2026, from ₹54.73 crore on March 31, 2026.
powered by IRIS

Aristo Bio-Tech and Lifescience Limited reported a 17.6% year-on-year rise in H1 FY27 net profit to ₹4.90 crore, even as revenue from operations declined 22.7% to ₹198.24 crore for the half year ended September 30, 2026. The result points to improved profitability despite a lower sales base.
Know Aristo Bio-Tech & Lifescience inside out
Results, valuation, peers and who's buying, in one view.
What did Aristo Bio-Tech and Lifescience report for H1 FY27?
Aristo Bio-Tech and Lifescience reported standalone, unaudited results for the April-September 2026 period after its board approved them on November 14, 2026. Revenue from operations fell to ₹198.24 crore from ₹256.45 crore in H1 FY26, a decline of ₹58.21 crore from the corresponding period a year earlier.
Total income, including other income, stood at ₹198.40 crore, compared with ₹256.54 crore in H1 FY26. Other income was ₹0.16 crore, marginally above ₹0.09 crore a year earlier. The filing therefore shows that nearly all of the company's income for the period came from its core operations.
Profit before tax increased to ₹6.60 crore from ₹5.54 crore, a rise of 19.0% year on year. Net profit rose to ₹4.90 crore from ₹4.17 crore, while basic and diluted earnings per share improved to ₹7.20 from ₹6.12.
Why did profit rise while revenue declined?
Aristo Bio-Tech and Lifescience's reported profit growth was linked to lower material consumption costs, according to the results summary. This cost movement allowed profit before tax and net profit to increase even though revenue from operations contracted sharply from the previous year's level.
The available results information indicates that ₹6.4 crore of the ₹6.6 crore pre-tax profit came from the core business. This suggests that the reported pre-tax performance was primarily generated by operations rather than other income or one-off items. Other income was only ₹0.16 crore during the half year.
The company did not publish an earnings-call transcript for the period. As a result, the available information does not provide management guidance, a detailed explanation of the revenue decline, or outlook commentary on demand, pricing, costs or future margins.
A results summary placed operating margin for H1 FY27 at 3.3%, compared with 2.1% in H1 FY26. The improvement in profitability metrics alongside lower revenue is relevant for investors because the result depended on cost performance during a period of lower sales.
Got a follow-up? Ask IRIS
How did the H1 FY27 result compare with recent periods?
Aristo Bio-Tech and Lifescience's H1 FY27 revenue was 85.3% higher than the ₹107.3 crore reported in H2 FY26, while net profit was 63.3% above the ₹3.0 crore reported in the preceding half year. The comparison shows a recovery from the second half of FY26, although revenue remained below the H1 FY26 level.
For the full financial year ended March 31, 2026, the company had reported revenue from operations of ₹36.37 crore and net profit of ₹7.18 crore. Those annual figures were reported with an unmodified audit opinion from statutory auditor Prakash Chandra Jain & Co. H1 FY27 revenue of ₹198.24 crore, as stated in the supplied half-year filing data, is substantially higher than that FY26 annual figure.
The company has historically released its April-September results 45 days after the end of the half year. It filed H1 results on November 14 in both 2024 and 2025, and the H1 FY27 results were also approved on November 14, 2026. The board meeting date had been disclosed to the NSE on November 3.
What balance-sheet and cash-flow items should investors note?
Aristo Bio-Tech and Lifescience reported trade receivables of ₹113.84 crore as of September 30, 2026, compared with ₹54.73 crore as of March 31, 2026. The rise of ₹59.11 crore is a significant disclosed balance-sheet movement and is relevant when assessing the conversion of reported sales into cash collections.
The supplied results information also describes net cash flow from financing activities as negative. It cites interest expense of ₹1.49 crore and finance cost of ₹0.14 crore, along with foreign-exchange loss, as factors in financing cash flows. Minor growth in long-term borrowings partly offset these items.
The higher receivables figure does not by itself establish the reasons for the increase or the eventual collection outcome. However, it places working-capital management alongside margin and revenue trends as a key item in the financial statements for shareholders to monitor.
For the market, the central data point is the divergence between the top line and profit. Revenue declined 22.7% year on year, while net profit rose 17.6%. Without management commentary, the filing supports an assessment of the reported numbers but does not support conclusions about whether the cost improvement or revenue trend will continue.
Conclusion
Aristo Bio-Tech and Lifescience closed H1 FY27 with net profit of ₹4.90 crore, up 17.6% year on year, despite revenue from operations falling to ₹198.24 crore. Lower material consumption costs supported profit before tax, while other income made only a small contribution to total income.
The next reported financial update will be important for evidence on revenue recovery, cost levels and trade-receivable collections. Investors will also watch for any company disclosure that explains the sales decline, addresses the increase in receivables, or provides guidance that was not available with the H1 FY27 results statement.


